

AN ACT

relating to the availability under Medicaid of certain drugs used to treat human immunodeficiency virus or prevent acquired immune deficiency syndrome.

BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS:

SECTION 1. Section 531.073, Government Code, is amended by amending Subsection (a) and adding Subsection (j) to read as follows:

(a) The executive commissioner, in the rules and standards governing the Medicaid vendor drug program and the child health plan program, shall require prior authorization for the reimbursement of a drug that is not included in the appropriate preferred drug list adopted under Section 531.072, except for any drug exempted from prior authorization requirements by federal law and except as provided by Subsection (j). The executive commissioner may require prior authorization for the reimbursement of a drug provided through any other state program administered by the commission or a state health and human services agency, including a community mental health center and a state mental health hospital if the commission adopts preferred drug lists under Section 531.072 that apply to those facilities and the drug is not included in the appropriate list. The executive commissioner shall require that the prior authorization be obtained by the prescribing physician or prescribing practitioner.

1        (j) The executive commissioner, in the rules and standards  
2 governing the Medicaid vendor drug program, may not require a  
3 clinical, nonpreferred, or other prior authorization for any  
4 antiretroviral drug, or a step therapy or other protocol, that  
5 could restrict or delay the dispensing of the drug except to  
6 minimize fraud, waste, or abuse. In this subsection,  
7 "antiretroviral drug" means a drug that treats human  
8 immunodeficiency virus infection or prevents acquired immune  
9 deficiency syndrome. The term includes:

10            (1) protease inhibitors;  
11            (2) non-nucleoside reverse transcriptase inhibitors;  
12            (3) nucleoside reverse transcriptase inhibitors;  
13            (4) integrase inhibitors;  
14            (5) fusion inhibitors;  
15            (6) attachment inhibitors;  
16            (7) CD4 post-attachment inhibitors;  
17            (8) CCR5 receptor antagonists; and  
18            (9) other antiretroviral drugs used to treat human  
19 immunodeficiency virus infection or prevent acquired immune  
20 deficiency syndrome.

21        SECTION 2. Section 533.005(a), Government Code, is amended  
22 to read as follows:

23        (a) A contract between a managed care organization and the  
24 commission for the organization to provide health care services to  
25 recipients must contain:

26            (1) procedures to ensure accountability to the state  
27 for the provision of health care services, including procedures for

1 financial reporting, quality assurance, utilization review, and  
2 assurance of contract and subcontract compliance;

3 (2) capitation rates that ensure the cost-effective  
4 provision of quality health care;

5 (3) a requirement that the managed care organization  
6 provide ready access to a person who assists recipients in  
7 resolving issues relating to enrollment, plan administration,  
8 education and training, access to services, and grievance  
9 procedures;

10 (4) a requirement that the managed care organization  
11 provide ready access to a person who assists providers in resolving  
12 issues relating to payment, plan administration, education and  
13 training, and grievance procedures;

14 (5) a requirement that the managed care organization  
15 provide information and referral about the availability of  
16 educational, social, and other community services that could  
17 benefit a recipient;

18 (6) procedures for recipient outreach and education;

19 (7) a requirement that the managed care organization  
20 make payment to a physician or provider for health care services  
21 rendered to a recipient under a managed care plan on any claim for  
22 payment that is received with documentation reasonably necessary  
23 for the managed care organization to process the claim:

24 (A) not later than:

25 (i) the 10th day after the date the claim is  
26 received if the claim relates to services provided by a nursing  
27 facility, intermediate care facility, or group home;

1 (ii) the 30th day after the date the claim  
2 is received if the claim relates to the provision of long-term  
3 services and supports not subject to Subparagraph (i); and

4 (iii) the 45th day after the date the claim  
5 is received if the claim is not subject to Subparagraph (i) or (ii);  
6 or

7 (B) within a period, not to exceed 60 days,  
8 specified by a written agreement between the physician or provider  
9 and the managed care organization;

10 (7-a) a requirement that the managed care organization  
11 demonstrate to the commission that the organization pays claims  
12 described by Subdivision (7)(A)(ii) on average not later than the  
13 21st day after the date the claim is received by the organization;

14 (8) a requirement that the commission, on the date of a  
15 recipient's enrollment in a managed care plan issued by the managed  
16 care organization, inform the organization of the recipient's  
17 Medicaid certification date;

18 (9) a requirement that the managed care organization  
19 comply with Section 533.006 as a condition of contract retention  
20 and renewal;

21 (10) a requirement that the managed care organization  
22 provide the information required by Section 533.012 and otherwise  
23 comply and cooperate with the commission's office of inspector  
24 general and the office of the attorney general;

25 (11) a requirement that the managed care  
26 organization's usages of out-of-network providers or groups of  
27 out-of-network providers may not exceed limits for those usages

1 relating to total inpatient admissions, total outpatient services,  
2 and emergency room admissions determined by the commission;

3 (12) if the commission finds that a managed care  
4 organization has violated Subdivision (11), a requirement that the  
5 managed care organization reimburse an out-of-network provider for  
6 health care services at a rate that is equal to the allowable rate  
7 for those services, as determined under Sections 32.028 and  
8 32.0281, Human Resources Code;

9 (13) a requirement that, notwithstanding any other  
10 law, including Sections 843.312 and 1301.052, Insurance Code, the  
11 organization:

12 (A) use advanced practice registered nurses and  
13 physician assistants in addition to physicians as primary care  
14 providers to increase the availability of primary care providers in  
15 the organization's provider network; and

16 (B) treat advanced practice registered nurses  
17 and physician assistants in the same manner as primary care  
18 physicians with regard to:

19 (i) selection and assignment as primary  
20 care providers;

21 (ii) inclusion as primary care providers in  
22 the organization's provider network; and

23 (iii) inclusion as primary care providers  
24 in any provider network directory maintained by the organization;

25 (14) a requirement that the managed care organization  
26 reimburse a federally qualified health center or rural health  
27 clinic for health care services provided to a recipient outside of

1 regular business hours, including on a weekend day or holiday, at a  
2 rate that is equal to the allowable rate for those services as  
3 determined under Section 32.028, Human Resources Code, if the  
4 recipient does not have a referral from the recipient's primary  
5 care physician;

6 (15) a requirement that the managed care organization  
7 develop, implement, and maintain a system for tracking and  
8 resolving all provider appeals related to claims payment, including  
9 a process that will require:

10 (A) a tracking mechanism to document the status  
11 and final disposition of each provider's claims payment appeal;

12 (B) the contracting with physicians who are not  
13 network providers and who are of the same or related specialty as  
14 the appealing physician to resolve claims disputes related to  
15 denial on the basis of medical necessity that remain unresolved  
16 subsequent to a provider appeal;

17 (C) the determination of the physician resolving  
18 the dispute to be binding on the managed care organization and  
19 provider; and

20 (D) the managed care organization to allow a  
21 provider with a claim that has not been paid before the time  
22 prescribed by Subdivision (7)(A)(ii) to initiate an appeal of that  
23 claim;

24 (16) a requirement that a medical director who is  
25 authorized to make medical necessity determinations is available to  
26 the region where the managed care organization provides health care  
27 services;

1           (17) a requirement that the managed care organization  
2 ensure that a medical director and patient care coordinators and  
3 provider and recipient support services personnel are located in  
4 the South Texas service region, if the managed care organization  
5 provides a managed care plan in that region;

6           (18) a requirement that the managed care organization  
7 provide special programs and materials for recipients with limited  
8 English proficiency or low literacy skills;

9           (19) a requirement that the managed care organization  
10 develop and establish a process for responding to provider appeals  
11 in the region where the organization provides health care services;

12           (20) a requirement that the managed care organization:

13               (A) develop and submit to the commission, before  
14 the organization begins to provide health care services to  
15 recipients, a comprehensive plan that describes how the  
16 organization's provider network complies with the provider access  
17 standards established under Section [533.0061](#);

18               (B) as a condition of contract retention and  
19 renewal:

20                   (i) continue to comply with the provider  
21 access standards established under Section [533.0061](#); and

22                   (ii) make substantial efforts, as  
23 determined by the commission, to mitigate or remedy any  
24 noncompliance with the provider access standards established under  
25 Section [533.0061](#);

26               (C) pay liquidated damages for each failure, as  
27 determined by the commission, to comply with the provider access

standards established under Section 533.0061 in amounts that are reasonably related to the noncompliance; and

(D) regularly, as determined by the commission, submit to the commission and make available to the public a report containing data on the sufficiency of the organization's provider network with regard to providing the care and services described under Section 533.0061(a) and specific data with respect to access to primary care, specialty care, long-term services and supports, nursing services, and therapy services on the average length of time between:

(i) the date a provider requests prior authorization for the care or service and the date the organization approves or denies the request; and

(ii) the date the organization approves a request for prior authorization for the care or service and the date the care or service is initiated;

(21) a requirement that the managed care organization demonstrate to the commission, before the organization begins to provide health care services to recipients, that, subject to the provider access standards established under Section 533.0061:

(A) the organization's provider network has the capacity to serve the number of recipients expected to enroll in a managed care plan offered by the organization;

(B) the organization's provider network includes:

(i) a sufficient number of primary care providers;



1 (ii) a sufficient variety of provider  
2 types;

3 (iii) a sufficient number of providers of  
4 long-term services and supports and specialty pediatric care  
5 providers of home and community-based services; and

6 (iv) providers located throughout the  
7 region where the organization will provide health care services;  
8 and

9 (C) health care services will be accessible to  
10 recipients through the organization's provider network to a  
11 comparable extent that health care services would be available to  
12 recipients under a fee-for-service or primary care case management  
13 model of Medicaid managed care;

14 (22) a requirement that the managed care organization  
15 develop a monitoring program for measuring the quality of the  
16 health care services provided by the organization's provider  
17 network that:

18 (A) incorporates the National Committee for  
19 Quality Assurance's Healthcare Effectiveness Data and Information  
20 Set (HEDIS) measures;

21 (B) focuses on measuring outcomes; and

22 (C) includes the collection and analysis of  
23 clinical data relating to prenatal care, preventive care, mental  
24 health care, and the treatment of acute and chronic health  
25 conditions and substance abuse;

26 (23) subject to Subsection (a-1), a requirement that  
27 the managed care organization develop, implement, and maintain an

1 outpatient pharmacy benefit plan for its enrolled recipients:

2 (A) that exclusively employs the vendor drug  
3 program formulary and preserves the state's ability to reduce  
4 waste, fraud, and abuse under Medicaid;

5 (B) that adheres to the applicable preferred drug  
6 list adopted by the commission under Section 531.072;

7 (C) that includes the prior authorization  
8 procedures and requirements prescribed by or implemented under  
9 Sections 531.073(b), (c), and (g) for the vendor drug program;

10 (C-1) that does not require a clinical,  
11 nonpreferred, or other prior authorization for any antiretroviral  
12 drug, as defined by Section 531.073, or a step therapy or other  
13 protocol, that could restrict or delay the dispensing of the drug  
14 except to minimize fraud, waste, or abuse;

15 (D) for purposes of which the managed care  
16 organization:

17 (i) may not negotiate or collect rebates  
18 associated with pharmacy products on the vendor drug program  
19 formulary; and

20 (ii) may not receive drug rebate or pricing  
21 information that is confidential under Section 531.071;

22 (E) that complies with the prohibition under  
23 Section 531.089;

24 (F) under which the managed care organization may  
25 not prohibit, limit, or interfere with a recipient's selection of a  
26 pharmacy or pharmacist of the recipient's choice for the provision  
27 of pharmaceutical services under the plan through the imposition of

1 different copayments;

2 (G) that allows the managed care organization or  
3 any subcontracted pharmacy benefit manager to contract with a  
4 pharmacist or pharmacy providers separately for specialty pharmacy  
5 services, except that:

6 (i) the managed care organization and  
7 pharmacy benefit manager are prohibited from allowing exclusive  
8 contracts with a specialty pharmacy owned wholly or partly by the  
9 pharmacy benefit manager responsible for the administration of the  
10 pharmacy benefit program; and

11 (ii) the managed care organization and  
12 pharmacy benefit manager must adopt policies and procedures for  
13 reclassifying prescription drugs from retail to specialty drugs,  
14 and those policies and procedures must be consistent with rules  
15 adopted by the executive commissioner and include notice to network  
16 pharmacy providers from the managed care organization;

17 (H) under which the managed care organization may  
18 not prevent a pharmacy or pharmacist from participating as a  
19 provider if the pharmacy or pharmacist agrees to comply with the  
20 financial terms and conditions of the contract as well as other  
21 reasonable administrative and professional terms and conditions of  
22 the contract;

23 (I) under which the managed care organization may  
24 include mail-order pharmacies in its networks, but may not require  
25 enrolled recipients to use those pharmacies, and may not charge an  
26 enrolled recipient who opts to use this service a fee, including  
27 postage and handling fees;

1 (J) under which the managed care organization or  
2 pharmacy benefit manager, as applicable, must pay claims in  
3 accordance with Section 843.339, Insurance Code; and

4 (K) under which the managed care organization or  
5 pharmacy benefit manager, as applicable:

6 (i) to place a drug on a maximum allowable  
7 cost list, must ensure that:

8 (a) the drug is listed as "A" or "B"  
9 rated in the most recent version of the United States Food and Drug  
10 Administration's Approved Drug Products with Therapeutic  
11 Equivalence Evaluations, also known as the Orange Book, has an "NR"  
12 or "NA" rating or a similar rating by a nationally recognized  
13 reference; and

14 (b) the drug is generally available  
15 for purchase by pharmacies in the state from national or regional  
16 wholesalers and is not obsolete;

17 (ii) must provide to a network pharmacy  
18 provider, at the time a contract is entered into or renewed with the  
19 network pharmacy provider, the sources used to determine the  
20 maximum allowable cost pricing for the maximum allowable cost list  
21 specific to that provider;

22 (iii) must review and update maximum  
23 allowable cost price information at least once every seven days to  
24 reflect any modification of maximum allowable cost pricing;

25 (iv) must, in formulating the maximum  
26 allowable cost price for a drug, use only the price of the drug and  
27 drugs listed as therapeutically equivalent in the most recent

1 version of the United States Food and Drug Administration's  
2 Approved Drug Products with Therapeutic Equivalence Evaluations,  
3 also known as the Orange Book;

4 (v) must establish a process for  
5 eliminating products from the maximum allowable cost list or  
6 modifying maximum allowable cost prices in a timely manner to  
7 remain consistent with pricing changes and product availability in  
8 the marketplace;

9 (vi) must:

10 (a) provide a procedure under which a  
11 network pharmacy provider may challenge a listed maximum allowable  
12 cost price for a drug;

13 (b) respond to a challenge not later  
14 than the 15th day after the date the challenge is made;

15 (c) if the challenge is successful,  
16 make an adjustment in the drug price effective on the date the  
17 challenge is resolved[7] and make the adjustment applicable to all  
18 similarly situated network pharmacy providers, as determined by the  
19 managed care organization or pharmacy benefit manager, as  
20 appropriate;

21 (d) if the challenge is denied,  
22 provide the reason for the denial; and

23 (e) report to the commission every 90  
24 days the total number of challenges that were made and denied in the  
25 preceding 90-day period for each maximum allowable cost list drug  
26 for which a challenge was denied during the period;

27 (vii) must notify the commission not later

1 than the 21st day after implementing a practice of using a maximum  
2 allowable cost list for drugs dispensed at retail but not by mail;  
3 and

4 (viii) must provide a process for each of  
5 its network pharmacy providers to readily access the maximum  
6 allowable cost list specific to that provider;

7 (24) a requirement that the managed care organization  
8 and any entity with which the managed care organization contracts  
9 for the performance of services under a managed care plan disclose,  
10 at no cost, to the commission and, on request, the office of the  
11 attorney general all discounts, incentives, rebates, fees, free  
12 goods, bundling arrangements, and other agreements affecting the  
13 net cost of goods or services provided under the plan;

14 (25) a requirement that the managed care organization  
15 not implement significant, nonnegotiated, across-the-board  
16 provider reimbursement rate reductions unless:

17 (A) subject to Subsection (a-3), the  
18 organization has the prior approval of the commission to make the  
19 reductions [~~reduction~~]; or

20 (B) the rate reductions are based on changes to  
21 the Medicaid fee schedule or cost containment initiatives  
22 implemented by the commission; and

23 (26) a requirement that the managed care organization  
24 make initial and subsequent primary care provider assignments and  
25 changes.

26 SECTION 3. Section 533.005, Government Code, as amended by  
27 this Act, applies to a contract entered into or renewed on or after

1 the effective date of this Act. A contract entered into or renewed  
2 before that date is governed by the law in effect on the date the  
3 contract was entered into or renewed, and that law is continued in  
4 effect for that purpose.

5       SECTION 4. If before implementing any provision of this Act  
6 a state agency determines that a waiver or authorization from a  
7 federal agency is necessary for implementation of that provision,  
8 the agency affected by the provision shall request the waiver or  
9 authorization and may delay implementing that provision until the  
10 waiver or authorization is granted.

11       SECTION 5. This Act takes effect September 1, 2019.

\_\_\_\_\_  
President of the Senate

\_\_\_\_\_  
Speaker of the House

I hereby certify that S.B. No. 1283 passed the Senate on April 17, 2019, by the following vote: Yeas 31, Nays 0; and that the Senate concurred in House amendment on May 23, 2019, by the following vote: Yeas 31, Nays 0.

\_\_\_\_\_  
Secretary of the Senate

I hereby certify that S.B. No. 1283 passed the House, with amendment, on May 17, 2019, by the following vote: Yeas 141, Nays 5, one present not voting.

\_\_\_\_\_  
Chief Clerk of the House

Approved:

\_\_\_\_\_  
Date

\_\_\_\_\_  
Governor